De CarlucciDJr., TavaresMR, ObaraMT, MartinsLA, HojaijFC, CerneaCR. 2008. Thyroid function after unilateral total lobectomy: risk factors for postoperative hypothyroidism. Arch Otolaryngol Head Neck Surg, 134:1076–1079.
2.
LiZ, QiuY, FeiY, XingZ, ZhuJ, SuA. 2020. Prevalence of and risk factors for hypothyroidism after hemithyroidectomy: a systematic review and meta-analysis. Endocrine, 70:243–255.
3.
HaugenBR, AlexanderEK, BibleKC, DohertyGM, MandelSJ, NikiforovYE, PaciniF, RandolphGW, SawkaAM, SchlumbergerM, SchuffKG, ShermanSI, SosaJA, StewardDL, TuttleRM, WartofskyL. 2016. 2015 American Thyroid Association Management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid, 26:1–133.
4.
SchummMA, LechnerMG, ShuML, OchoaJE, KimJ, TsengCH, LeungAM, YehMW. 2021. Frequency of thyroid hormone replacement after lobectomy for differentiated thyroid cancer. Endocr Pract, 27:691–697.
5.
CoxC, BosleyM, SoutherlandLB, AhmadiS, PerkinsJ, RomanS, SosaJA, Carneiro-PlaD. 2018. Lobectomy for treatment of differentiated thyroid cancer: can patients avoid postoperative thyroid hormone supplementation and be compliant with the American Thyroid Association guidelines?. Surgery, 163:75–80.
6.
XuS, HuangY, HuangH, ZhangX, QianJ, WangX, XuZ, LiuS, LiuJ. 2022. Optimal serum thyroid-stimulating hormone level for patients with papillary thyroid carcinoma after lobectomy. Thyroid, 32:138–144.
7.
ParkJH, LeeYM, LeeYH, HongSJ, YoonJH. 2018. The prognostic value of serum thyroid-stimulating hormone level post-lobectomy in low- and intermediate-risk papillary thyroid carcinoma. J Surg Oncol, 118:390–396.
8.
LeeMC, KimMJ, ChoiHS, ChoSW, LeeGH, ParkYJ, ParkDJ. 2019. Postoperative thyroid-stimulating hormone levels did not affect recurrence after thyroid lobectomy in patients with papillary thyroid cancer. Endocrinol Metab (Seoul), 34:150–157.
